Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK - Get Free Report) announced a dividend on Thursday, May 16th, investing.com reports. Shareholders of record on Tuesday, May 21st will be given a dividend of 15.10 per share by the biopharmaceutical company on Friday, May 17th. This represents a yield of 99.87%. The ex-dividend date of this dividend is Monday, May 20th. This is a boost from Merrimack Pharmaceuticals's previous dividend of $1.50.
Merrimack Pharmaceuticals Price Performance
Shares of NASDAQ MACK remained flat at $15.13 during trading hours on Thursday. The company had a trading volume of 869,211 shares, compared to its average volume of 159,801. The firm has a fifty day moving average of $14.80 and a 200-day moving average of $13.85. Merrimack Pharmaceuticals has a fifty-two week low of $11.53 and a fifty-two week high of $15.89. The stock has a market cap of $219.84 million, a PE ratio of -189.13 and a beta of 1.45.
Merrimack Pharmaceuticals (NASDAQ:MACK - Get Free Report) last announced its earnings results on Wednesday, May 15th. The biopharmaceutical company reported ($0.03) earnings per share (EPS) for the quarter.
Wall Street Analyst Weigh In
Separately, StockNews.com cut shares of Merrimack Pharmaceuticals from a "hold" rating to a "sell" rating in a research note on Monday.
Read Our Latest Report on MACK
About Merrimack Pharmaceuticals
(
Get Free Report)
Merrimack Pharmaceuticals, Inc operates as a biopharmaceutical company in the United States. The company was incorporated in 1993 and is headquartered in Cambridge, Massachusetts.
Further Reading
Before you consider Merrimack Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Merrimack Pharmaceuticals wasn't on the list.
While Merrimack Pharmaceuticals currently has a "hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
